Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Coherus Oncology, Inc. Common Stock

CHRS

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.

Last trade $0.4367
Day change -$0.0692 (-13.68%)
Day range $0.435 – $0.509
Volume 2,500,231
Market cap $78M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$78.81M
Price / earnings
—
Price / book
3.12×
Price / sales
1.47×
EV / sales
1.45×
EV / EBITDA
-0.54×

Profitability

Earnings per share
-$0.88
Return on assets
-79.45%
Return on equity
-538.38%
Dividend yield
0%

Liquidity and leverage

Debt / equity
2.08×
Current ratio
1.51×
Quick ratio
1.45×
Cash ratio
0.71×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$652.39M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CHRS, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$14.27M$14.31M$12.31M$12.75M$11.57M$10.25M$7.6M$7.73M
Cost of revenue$4.09M$4.24M$3.81M$4.05M$3.72M$3.4M$2.65M$2.75M
Gross profit$10.18M$10.07M$8.5M$8.7M$7.85M$6.86M$4.95M$4.98M
Selling, general and administrative$21.23M$20.95M$23.1M$23.61M$24.93M$26.04M$26.03M$29.61M
Research and development$22.61M$21.44M$21.54M$30.97M$27.25M$26.31M$24.36M$20.76M
Total operating expenses$43.83M$42.4M$44.65M$54.58M$52.18M$52.35M$50.38M$50.37M
Operating income-$33.65M-$32.33M-$36.15M-$45.88M-$44.33M-$45.49M-$45.44M-$45.38M
Interest expense-$2.78M-$2.32M-$2.19M-$2.25M-$2.33M-$2.28M-$2.15M-$1.91M
Income before taxes-$38.88M-$33.35M-$36.94M-$46.35M-$44.52M-$44.86M-$47.4M-$46.09M
Income taxes$0$0$0$0$0$0$0$0
Net income-$39.33M-$20.63M-$38.33M-$37.64M-$35.53M$297.77M-$56.57M-$50.7M
Net income attributable to common shareholders-$39.33M-$20.63M-$38.33M-$37.64M-$35.53M$297.77M-$56.57M-$50.7M
EBITDA-$32.8M-$31.47M-$35.27M-$44.98M-$43.37M-$44.47M-$44.39M-$44.35M
Basic earnings per share-$0.25-$0.13-$0.28-$0.31-$0.31$2.57-$0.49-$0.44
Diluted earnings per share-$0.25-$0.13-$0.28-$0.31-$0.31$2.57-$0.49-$0.44

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Coherus Oncology: 3 Key Takeaways for Long-Term Investors

Coherus Oncology announced a 30% workforce reduction to lower quarterly operating costs by $6-7 million, reducing the revenue needed for cash breakeven from $30-35 million to $25-30 million per quarter. The company is narrowing clinical development of tagmokitug to second-line esophageal cancer treatment. LOQTORZI achieved $14 million in Q3 net sales with 25% year-over-year growth, and 75% of surveyed oncologists now view it as standard-of-care treatment for nasopharyngeal carcinoma. However, with less than 12 months of cash runway, execution and sales growth are critical for survival.

Zacks Investment Research

Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates

Coherus Oncology reported a quarterly loss of $0.25 per share, missing the consensus estimate of $0.22, with revenues of $14.27 million falling 10.25% short of expectations. The stock has declined 45.8% year-to-date, significantly underperforming the S&P 500's 7.8% gain. Despite the miss, the company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.

GlobeNewswire Inc.

Coherus Oncology to Report Second Quarter 2026 Financial Results on August 5, 2026

Coherus Oncology announced it will release second quarter 2026 financial results on August 5, 2026, followed by a conference call at 5:00 p.m. EDT. The company will discuss financial performance and provide a business update on its oncology pipeline, including its approved PD-1 inhibitor LOQTORZI and mid-stage clinical candidates.

GlobeNewswire Inc.

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

Coherus Oncology and Zumutor Biologics announced a Phase 1 clinical collaboration to evaluate ZM008, an anti-LLT1 monoclonal antibody, in combination with LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, in patients with various solid tumors. The trial will enroll up to 45 patients and aims to evaluate safety, tolerability, and identify biomarkers for personalized therapies. Both companies retain commercial rights to their respective compounds.

Benzinga

Coherus Oncology, Inc. Announces Closing of Public Offering of Common Stock

Coherus Oncology completed a public offering of 28.6 million shares at $1.75 per share, raising approximately $50.1 million in gross proceeds. The company plans to use the funds to support commercialization of LOQTORZI (toripalimab-tpzi), continue clinical development of pipeline candidates, and for general corporate purposes. The offering was led by healthcare investors including Janus Henderson, HBM Healthcare Investments, and Samsara BioCapital.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.